ZNF484

Across TCGA pan-cancer cohorts, ZNF484 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ZNF484 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher ZNF484 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZNF484 expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

LIHC, UCEC, and KIRC are the cancer types where ZNF484 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.080	0.544	<.001	12	view →
UCEC	DFS	Median	II,III,IV	0.922	0.304	.012	8	view →
KIRC	OS	Median	All	0.181	0.655	.046	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
BLCA	OS	Median	II,III,IV	1.000	0.702	.048	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ZNF484–LIHC (DFS)

Open the LIHC breakdown →